Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 1,055

Document Document Title
WO/2013/184734A1
The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are Factor VIIa inhibitors which may be used as medicaments.  
WO/2013/172171A1
A cyclic carbodiimide compound represented by formulas (O-1) or (O-2) can be used for producing a polyester film that does not contain isocyanates with a small molecular weight and that has excellent thickness uniformity without any thic...  
WO/2013/139697A1
The conformationally restricted, spatially defined macrocyclic ring system of formula (I) is constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. Macrocycles described by this ring system I ar...  
WO/2013/119184A1
The invention relates to the synthesis of peptides, proteins and related bioconjugates, and in particular, to such synthesis using a peptide ligation method whereby a C-terminal salicylaldehyde ester peptide is reacted with an aminoacyl-...  
WO/2013/116682A1
The invention relates generally to macrocyclic compounds of formula I and their therapeutic use. More particularly, the invention relates to macrocyclic compounds that modulate the activity of IL-17 and/or are useful in the treatment of ...  
WO/2013/104613A1
The invention relates to a compound of formula (I) wherein A, B, D and R1 to R6 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.  
WO/2013/098572A1
Present invention refers to complex-forming compounds of the general formula and the use and preparation thereof.  
WO/2013/088162A1
Compounds of general formula (I) wherein X, X', Y, Y', A and A' are as defined herein have anitmicrobial activity.  
WO/2012/142457A2
The present invention relates to a macrolactam compound, and methods for treating a subject with malaria using the macrolactam compound, represented by the following structural formula (l), wherein the values and preferred values of the ...  
WO/2012/069859A1
The invention relates to fluorescent dyes of formula (I) which at a sensitive to sodium ions and optionally also to potassium ions, and to.' salts, of those compounds which are capable to salt formation - in this formula Rx is a group of...  
WO/2011/155624A1
Disclosed is a cyclic carbodiimide compound represented by formula (i), the compound being useful as a terminal-blocking agent for polymers. (In formula (i), X is a specific di- or tetravalent group; q is 0 when X is the divalent group, ...  
WO/2011/149250A2
The present invention relates to a tricarbonyl technetium-99m or rhenium-188 label ring RGD derivative, a preparation method thereof, and a pharmaceutical composition containing the derivative as an active ingredient for use in the diagn...  
WO/2011/129501A1
The present invention relates to a method for preparing a poly(ether sulfonimide or -amide)copolymer using cyclic oligomers, and more particularly, to a method for preparing a poly(ether sulfonimide or -amide)copolymer by preparing cycli...  
WO/2011/087155A1
Provided is a resin composition which comprises polylactic acid, releases no isocyanate group-containing compound in the production process thereof, is highly resistant to hydrolysis and has a low environmental burden. The resin composit...  
WO/2011/069995A1
The present invention relates firstly to the discovery of the previously unknown 24- membered cyclooctadepsipeptides PF1022-V, PF1022-W, XRB-C894, XRB-C942, XRB-C976, XRB-C1010, XRB-C1044, XRB-E922, XRB-E956, XRB-E990, XRB-E1024, XRB-S95...  
WO/2011/069045A2
The disclosure relates generally to methods for the preparation of a family of natural compounds, the syrbactins and their analogs.  
WO/2011/001052A1
The invention relates to a targeting agent, to which at least one cryptophycin is attached, of the formula (I), where: R1 is a halogen atom and R2 is an OH group, an acyl group derived from an amino acid AA or a (C1-C4)alkanoyloxy group;...  
WO/2010/146404A1
The invention relates to adamantane diaza-crown ether derivatives and the use of mono and diaza-crown ether adamantine derivatives in treatment, especially in tumor treatment. Adamantane aza-crown ethers were obtained by reaction of the ...  
WO/2010/119906A1
Disclosed is a novel herbicide. A haloalkylsulfonanilide derivative represented by formula (1) or an agrochemically acceptable salt thereof. In formula (1), Z represents –C(R9)(R10)- or –N(R11)-; A represents an oxygen atom, a sulfur...  
WO/2010/108058A2
Compounds that stimulate fibroblast growth factor production, and thus cell growth are provided. Also provided are compositions comprising the compounds and methods of using the compounds. The compounds can be used to treat wounds, to ex...  
WO/2010/108067A1
Disclosed are compounds, pharmaceutical compositions containing the compounds, methods for using the compounds and processes for making the compounds. More specifically, the disclosure relates to alpha-(N-benzenesulfonamido)cycloalkyl co...  
WO/2010/102717A1
The present application relates to novel alkyl carboxylic acids, having an oxo-substituted aza-heterocyclical partial structure, to a method for producing same, to the use thereof for treating and/or preventing disease, and to the use th...  
WO/2010/071212A1
Provided is a method for capping the end of a polymer by means of a carbodimide composition without freeing an isocyanate compound. This method uses as the polymer end-capping agent a compound which has one carbodimide group and which co...  
WO/2010/071213A1
Provided is a resin composition which contains polyester and has no odor caused by a free isocyanate compound. This resin composition contains a terminal-modified polyester (component A) and a compound (component B) which has one carbodi...  
WO/2010/071211A1
Provided are cyclic carbodiimide compounds that are useful as end-sealing agents for polymer compounds. The cyclic carbodiimide compounds are represented by formula (i). (in the formula, X is a 2-valent group, or a 4-valent group represe...  
WO/2010/043218A2
The invention relates to a ligand of formula (I), where (CH-R1) and (CH-R1’) are substituted or non-substituted methylene bridges; the individual R1 and R1’, and R3 and R3’, are each selected independently of each other from hydrog...  
WO/2010/021693A2
The invention provides novel heterocyclic compounds, pharmaceutical compositions and methods of treatment that modulate levels of MIF expression and treat disorders associated with high or low levels of MIF expression.  
WO/2010/022249A2
The invention provides macrocyclic compounds and methods for their synthesis and use. In particular, the invention provides macrocyclic compounds that modulate the activity of tumor necrosis factor alpha and/or are useful in the treatmen...  
WO/2009/146802A1
The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary preventio...  
WO/2009/127338A1
The present invention relates to novel carboxylic acid derivates of the formula (I), having an oxo-substituted azaheterocyclic partial structure, method for the production thereof, use thereof for treating and/or preventing illnesses and...  
WO/2009/092293A1
A compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof, which can inhibit HIV replication.  
WO/2009/037642A1
Disclosed are heterocyclic scaffolds useful, for example, for solid-phase organic synthesis of combinatorial libraries and methods for the preparation thereof. Also disclosed are libraries, including combinatorial libraries, and methods ...  
WO/2008/138527A2
The present invention relates to novel halogenated aromatic oxime compounds and compositions comprising said compounds, and to the use of the novel compounds and compositions as anti-fouling agents.  
WO/2008/130464A1
The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants ther...  
WO/2008/125201A1
The present invention relates to polyurethane compositions which cure by radiation and thermal action with crosslinking, and use thereof for the production of holographic media. The polyurethane compositions of the invention comprise A) ...  
WO/2008/116302A1
The present invention relates to novel compounds of the formula (I), wherein R'-R7, X, Y, D and n are as defined in the specification. These compounds are cysteine protease inhibitors which include but are not limited to inhibitors of ca...  
WO/2008/110583A1
The present invention relates to a compound of Formula (I), its geometrical isomers, in an optically active form as enantiomers, diastereomers, as well as in the form of racemate, as well as pharmaceutically acceptable salts thereof, whe...  
WO/2008/009750A2
The invention relates to novel macrocyclic compounds of the Formula (I) in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments...  
WO/2007/145835A2
Benzamide derivatives of formula ( I ) are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders, formula (I), wherein R1, R 2, R 3, R 4, R 5, R 6, R 7, R 8, and n...  
WO/2007/104135A1
A bifunctional polyazamacrocyclic chelating agent of the formula (I): wherein: and the variables A, L, Q, Q1, X, Y, Z, Z1, m, n and r are as defined in the description of the present application. Also described is a complex of the above ...  
WO/2007/102590A1
Disclosed is an optically active compound represented by the general formula (I): (I) wherein X1, X2, X3 and X4 independently represent -NH2, -N(CH3)2, -H, -CpF2p+1, -SCqH2q+1, -CrH2r+1, -OCsH2s+1, -F, -I, -Br, -Cl, -COOH, -COOCtH2t+1, -...  
WO/2007/079869A2
The invention relates to cyclic aminals, obtained from fragrance aldehydes or biocidal aldehydes, suitable for example for perfuming or conserving washing and cleaning agents and the materials treated with the washing and cleaning agents...  
WO/2007/074171A1
Methods for the synthesis of various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds (I) and their pharmaceutically acceptable salt derivatives are provided. The compounds of the invention are claimed and a...  
WO/2007/074169A2
The present invention relates to various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds, their pharmaceutically acceptable salt derivatives, and their methods of use.  
WO/2007/039463A1
The present invention provides compounds of formula (I) where R1 to R4 are as defined herein which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further prov...  
WO/2007/031213A1
Novel dioxazine- and oxadiazine-substituted arylamides of the formula (I) in which A1, A2, R1, R2, R3, R4 and R5 are as defined in the description, a plurality of processes for preparing these compounds and their use for controlling pest...  
WO/2007/012464A1
The present invention relates to macrolide conjugates of pyrrolizine and indolizine derivatives with macrocyclic antibiotics and derivatives thereof. The macrolide conjugates are potent inhibitors of 5-lipoxygenase and cyclooxygenase and...  
WO/2007/000098A1
The invention, discloses substituted p-trifluoromethyl phenylethers of formula (I), the preparation and the use thereof, wherein each substituent is defined as in the description. The compounds of the invention have broad spectrum activi...  
WO/2006/127364A1
Compounds of formula (I), in which B1 and X1 are together alkylene which is unsubstituted or substituted with =O and having one CH2 moiety unreplaced or replaced with CH=CH, O, NH or N(alkyl), which inhibit the activity of antiapoptotic ...  
WO/2006/074950A1
The invention relates to novel macrocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base fo...  

Matches 101 - 150 out of 1,055